摘要
目的初步探讨晚期非小细胞肺癌患者在凝血常规指导下应用预防性抗凝治疗的临床应用。方法将本院近3年无抗凝禁忌症的晚期非小细胞肺癌患者68例回顾性分成两组(治疗组35例,对照组33例),治疗组给予低分子肝素钙联合小剂量华法林治疗,对照组则不给予任何抗凝用药,其余治疗条件、方案大致相同。比较两组患者3月内血浆纤维蛋白原变化、有无静脉血栓、肿瘤进展及死亡情况。结果治疗组静脉血栓1例,肿瘤进展12例,死亡3例,纤维蛋白原降低;对照组静脉血栓7例,肿瘤进展20例,死亡9例,纤维蛋白原无明显减低。结论在凝血常规的指导下预防性抗凝治疗能有效预防晚期非小细胞肺癌患者静脉血栓形成,可延缓肿瘤进展、不同程度延长生存时间。
Objective To discuss preliminarily the clinical application of prophylactic anticoagulation in therapy ad- vanced non small cell lung cancer by the guidance of routine coagulation. Methods 68 patients who were advanced non small cell lung cancer patients and had no contraindications to anticoagulation in the near 3 years were divided into two groups. The treatment group were treated with low molecular heparin calcium combined with small dose of warfarin therapy, and the control group was not given any other anticoagulant medication, but the other treatment conditions and options were roughly the same. The plasma fibrinogen changes, with or without venous thrombosis and tumor progression or death were compared between the 2 groups in 3 months. Results 1 case had venous thrombosis, 12 cases had tumor progression,3 cases died, FIB decreased in the 35 cases of treatment group. And 7 cases had venous thrombosis, 20 cases had tumor pro- gression,9 cases died, FIB did not significantly decreased in the 33 cases of control group. Conclusion Prophylactic anticoagulant therapy on advanced non small cell lung cancer by the guidance of routine coagulation could effectively pre- vent venous thrombosis, delay tumor progression, and prolong the survival time in different degree.
出处
《中南医学科学杂志》
CAS
2012年第5期493-495,共3页
Medical Science Journal of Central South China
关键词
非小细胞肺癌
低分子肝素钙
华法林
non small cell lung cancer
low molecular heparin calcium
warfarin
